TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8155034
Drug: Methazolamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (50 mg twice daily) for 12 weeks
Study: 6766274
Drug: Amoxicillin, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 6 gm by mouth every 24 hours
Study: 30621764
Drug: Calmangafodipir (PP100‐01)
Normalized name: mangafodipir
DrugBank: Calmangafodipir (DB18398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calmangafodipir (PP100‐01) co-administered with a 12-h NAC regimen
Study: 30621764
Drug: NAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC treatment alone
Study: 28738857
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-test kits (one of five intervention arms)
Study: 28738857
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-test kits with financial incentive (fixed or lottery amount)
Study: 28738857
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-test kits with phone call reminders
Study: 25994445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group attending weekly lectures
Study: 24099350
Drug: Qishe Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishe Pill (3.75 g twice a day for 28 days)
Study: 24099350
Drug: Placebo (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3.75 g twice a day for 28 days)
Study: 21216583
Drug: Chromium chloride
Normalized name: Chromium chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium chloride 400 μg
Study: 15117055
Drug: Lutein 10
Normalized name: lutein 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 10 mg (Group 1)
Study: 15117055
Drug: Lutein 10
Normalized name: lutein 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 10 mg/antioxidants/vitamins and minerals broad spectrum supplementation formula (Group 2)
Study: 11046202
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin solution
Study: 11605923
Drug: 6% hetastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hetastarch solution
Study: 16923636
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (10 Hz, 5 daily sessions)
Study: 15224788
Drug: Sodium sulfacetamide
Normalized name: sodium sulfacetamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium sulfacetamide lotion 10%
Study: 15224788
Drug: Selenium sulfide
Normalized name: Selenium Sulfide
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenium sulfide lotion 2.5%
Study: 11513054
Drug: Lignocaine 50
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 50 mg
Study: 9267856
Drug: Idebenone 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 90 mg t.i.d.
Study: 31464558
Drug: Booster CYD‐TDV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster CYD‐TDV dose (Group 1)
Study: 24330903
Drug: High-dose unilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose unilateral brief pulse ECT (1.0 millisecond)
Study: 21394895
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (rotated drug pairs) in SRG
Study: 21394895
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (rotated drug pairs) in IRG
Study: 10356669
Drug: VIP/P-1 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP/P-1 (25 micrograms vasoactive intestinal polypeptide combined with 1.0 mg phentolamine mesylate)
Study: 10356669
Drug: VIP/P-2 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP/P-2 (25 micrograms vasoactive intestinal polypeptide combined with 2.0 mg phentolamine mesylate)
Study: 27160892
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2 through 90)
Study: 27160892
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2 through 90)
Study: 22730539
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) at 5 mg/m², repeated after 3 weeks
Study: 18520604
Drug: High-dose MDMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MDMA (1.6 mg/kg)
Study: 31375749
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution with EB
Study: 31375749
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution without EB
Study: 22384546
Drug: Tongguan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongguan Capsule
Study: 30043582
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine
Study: 15673175
Drug: Perspective imposed
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perspective imposed by language (e.g., 'You are driving a car' or 'You are fueling a car')
Study: 15673175
Drug: Actions directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actions directed toward parts of the car (e.g., roof or wheels)
Study: 11729034
Drug: Cortisol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (15 mg)
Study: 2203486
Drug: Intravenous RO
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous RO 42-5892 (100 micrograms/kg)
Study: 2203486
Drug: Intravenous RO
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous RO 42-5892 (1000 micrograms/kg)
Study: 31958667
Drug: Shared a
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shared a lot treatment (another child shared 6 stickers)
Study: 31958667
Drug: Shared a
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shared a little treatment (another child shared 1 sticker)
Study: 10562784
Drug: Ketoprofen 0.3-3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.3-3.0 mg kg-1 administered pre-emptively i.v. during operation
Study: 2110787
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine and hyoscine (scopolamine)
Study: 2110787
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam plus intramuscular morphine and hyoscine
Study: 22836859
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (<20 g of fat/d) for 4 weeks in the suggestive group
Study: 21329887
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (PUUO without treatment)
Study: 11288011
Drug: Reviparin (low-molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin (low-molecular weight heparin) administered once daily subcutaneously for 7 to 10 days
Study: 23230457
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine
Study: 3297467
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine + oral captopril (50 mg)
Study: 26860796
Drug: JianYuTangKang (JYTK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JianYuTangKang (JYTK) plus metformin
Study: 18467730
Drug: Current therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapy
Study: 12910567
Drug: 150 international
Normalized name: CONDOM,INTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 international units of human IFN alfa administered oromucosally 3 times per day for 24 weeks
Study: 10781467
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg spinal bupivacaine
Study: 1485370
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (4.6-7.3 mg)
Study: 1485370
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone tablets (9.1 mg)
Study: 1485370
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone syrup (9.1 mg)
Study: 1485370
Drug: Rectal oxycodone
Normalized name: oxycodone Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal oxycodone suppository (30 mg)
Study: 2858149
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy of dynamic type or simple basal therapy
Study: 30720931
Drug: Topical Daprodustat
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Topical Daprodustat (1.0% at 100 mg/cm2 for 14 days)
Study: 22149337
Drug: Ecallantide, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecallantide, a potent and specific plasma kallikrein inhibitor, administered subcutaneously.
Study: 19156709
Drug: Antidepressants augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants augmented with atypical antipsychotics (AAP) for more than 2 weeks (n = 100)
Study: 19156709
Drug: Antidepressants only
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants only (non‐AAP group, n = 172)
Study: 17548728
Drug: Neopterin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neopterin levels > or = 12.11 nmol/L at 4 months after ACS
Study: 17548728
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin among subjects with neopterin levels > or = 12.11 nmol/L at baseline
Study: 11246058
Drug: Aspirin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (160 mg/d)
Study: 11246058
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin (75 mg/d) and warfarin (INR 2.0‐2.5)
Study: 2692344
Drug: Diclofenac-Na 100
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-Na 100 mg
Study: 23333095
Drug: High polyphenol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High polyphenol olive oil (961 mg/kg)
Study: 23333095
Drug: Moderate polyphenol
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate polyphenol olive oil (289 mg/kg)
Study: 18771406
Drug: PRO 140
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRO 140 2 mg/kg
Study: 18771406
Drug: PRO 140
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRO 140 5 mg/kg
Study: 8688387
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (60 mg daily)
Study: 30444150
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT-tablet (5000, 10,000, or 20,000 JAU) for 14 days
Study: 30444150
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT-tablet (up-dosing regimen: 5,000 JAU on days 1-3, 10,000 JAU on days 4-7, 20,000 JAU on days 8-14) for 14 days
Study: 29288190
Drug: Organ-saving treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ-saving treatment using short-course radiotherapy
Study: 24707863
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine sulphate (MOR)
Study: 12646763
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of 2 mg clonazepam
Study: 12646763
Drug: Oral (p.o.)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (p.o.) administration of 2 mg clonazepam
Study: 12646763
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of 2 mg clonazepam
Study: 8807096
Drug: Debulking chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debulking chemotherapy (vincristine, adriamycin, and dexamethasone or methylprednisolone)
Study: 1381611
Drug: arotinolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: arotinolol (10 mg bid)
Study: 27798510
Drug: Denosumab on
Normalized name: Denosumab only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab on top of standard treatment (calcium and vitamin D), n = 46
Study: 27798510
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone, n = 44
Study: 10916043
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (bromocriptine, lisuride, cabergoline, ropinirole)
Study: 10916043
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of L-dopa (added as a second step if necessary)
Study: 8885585
Drug: Bupropion 3
Normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 3 to 6 mg/kg per day, administered twice daily
Study: 30241119
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only (Control group)
Study: 12197840
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon‐α 2a/2b plus ribavirin
Study: 6781156
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of dihydralazin and propranolol
Study: 6781156
Drug: Antihypertensive standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive standard therapy
Study: 29480916
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Treatment (OMT) for a maximum of 20 minutes
Study: 29141653
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with access to a website with PRB resources.
Study: 19378515
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg kg(‐1) of rocuronium (1 ED95)
Study: 8799402
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug given)
Study: 6386002
Drug: Dipyridamole (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (225 mg/day) and Aspirin (975 mg/day)
Study: 6371535
Drug: Dipyridamole and
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole and Aspirin
Study: 30976908
Drug: LBW-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBW-based dosing of palonosetron
Study: 30976908
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing of palonosetron (0.075 mg)
Study: 22971669
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg/d
Study: 16970087
Drug: Yanshu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yanshu Injection (20 ml daily)
Study: 11227684
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy intervention during the first dressing change (Group A)
Study: 3654132
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL antiseptic soap
Study: 28284187
Drug: RISKIT-CJS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RISKIT-CJS intervention in addition to treatment as usual
Study: 16396771
Drug: ViGePP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ViGePP regimen (gemcitabine, vinorelbine, procarbazine, and prednisone) administered every 4 weeks up to six courses.
Study: 11531149
Drug: Insulin-meal interval
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-meal interval of 15 min
Study: 11531149
Drug: Insulin-meal interval
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-meal interval of 30 min
Study: 9280186
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg/d as amino acid chelate for 3 weeks)
Study: 27009070
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening (T0)
Study: 27009070
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening (T1)
Study: 22108915
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral estradiol (n=6)
Study: 22108915
Drug: 50 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg/day transdermal 17β‐estradiol (n=5)
Study: 18028044
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient-controlled analgesia (IV PCA) (1 mg morphine/dose)
Study: 12565114
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient-controlled analgesia (IV PCA)
Study: 15704203
Drug: Denufosol (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denufosol (10, 20, 40, and 60 mg, administered by inhalation via the Pari LC Star nebulizer)
Study: 15704203
Drug: Denufosol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denufosol (maximum tolerated dose)
Study: 1702916
Drug: Pygeum africanum
Normalized name: Pygeum africanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pygeum africanum extract (50 mg capsules, 1 capsule in the morning and 1 capsule in the evening for 60 days)
Study: 1702916
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 capsule in the morning and 1 capsule in the evening for 60 days)
Study: 531221
Drug: 3000 microgram
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 microgram (155)-methyl PGF2 alpha methyl ester (U-36,384) via slow release vaginal suppository
Study: 531221
Drug: 500 microgram
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microgram 16-phenoxy-omega-tetranor PGE2 methyl sulfonylamide (Sulproston) via intramuscular injection at 4 hour intervals, totaling 1250 +/- 154 microgram
Study: 15814549
Drug: corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid therapy
Study: 7709947
Drug: Silver-coated catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver-coated catheter (5% silver oxide) in women not receiving antibiotics
Study: 7709947
Drug: Silver-coated catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver-coated catheter (5% silver oxide) in men not receiving antibiotics
Study: 7709947
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard silicone elastomer-coated latex catheter) in men not receiving antibiotics
Study: 2704247
Drug: Apomorphine (0.009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (0.009 mg/kg)
Study: 29527812
Drug: Closed-incision negative
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-incision negative pressure therapy (ciNPT)
Study: 24934734
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy alone
Study: 17328989
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg daily as maintenance therapy
Study: 12612903
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (3 MU 3 times a week) plus 1000‐1200 mg/day ribavirin for 1 year
Study: 10234597
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily by mouth
Study: 25641533
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and glycoprotein IIb/IIIa inhibitor
Study: 23425430
Drug: Fixed-combination brinzolamide
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC)
Study: 21271174
Drug: Sufentanil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.1 µg/kg)
Study: 21271174
Drug: Clonidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.5 µg/kg)
Study: 9671875
Drug: Goserelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin plus antiandrogen therapy
Study: 9671875
Drug: Leuprolide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide plus antiandrogen therapy
Study: 9671875
Drug: Leuprolide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide plus flutamide therapy
Study: 9671875
Drug: Goserelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin plus bicalutamide therapy
Study: 9671875
Drug: Goserelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin plus flutamide therapy
Study: 9671875
Drug: Leuprolide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide plus bicalutamide therapy
Study: 8044010
Drug: Xijian Tongshuan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xijian Tongshuan pill (XJTS)
Study: 8044010
Drug: Cyclandelate capsule
Normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate capsule (Control group B)
Study: 25720929
Drug: FUSION BIOLINE
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FUSION BIOLINE heparin-coated vascular graft